Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

From Animal Poisons and Venoms to Medicines: Achievements, Challenges and Perspectives in Drug Discovery

Full text
Author(s):
Show less -
Figueiredo Bordon, Karla de Castro [1] ; Cologna, Camila Takeno [1] ; Fornari-Baldo, Elisa Correa [2] ; Pinheiro-Junior, Ernesto Lopes [1] ; Cerni, Felipe Augusto [1] ; Amorim, Fernanda Gobbi [3] ; Pino Anjolette, Fernando Antonio [4] ; Cordeiro, Francielle Almeida [1] ; Wiezel, Gisele Adriano [1] ; Cardoso, Iara Aime [1] ; Ferreira, Isabela Gobbo [1] ; de Oliveira, Isadora Sousa [1] ; Boldrini-Franca, Johara [5] ; Pucca, Manuela Berto [6] ; Baldo, Mateus Amaral [2] ; Arantes, Eliane Candiani [1]
Total Authors: 16
Affiliation:
[1] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept BioMol Sci, Lab Anim Toxins, Ribeirao Preto - Brazil
[2] Univ Paulista, Hlth & Sci Inst, Sao Jose Do Rio Preto - Brazil
[3] Vila Velha Univ, Postgrad Program Pharmaceut Sci, Vila Velha - Brazil
[4] Fed Inst Educ Sci & Technol Parana, Dept Pharm, Palmas - Brazil
[5] Vila Velha Univ, Postgrad Program Ecosyst Ecol, Vila Velha - Brazil
[6] Univ Fed Roraima, Med Sch, Boa Vista, Parana - Brazil
Total Affiliations: 6
Document type: Review article
Source: FRONTIERS IN PHARMACOLOGY; v. 11, JUL 24 2020.
Web of Science Citations: 0
Abstract

Animal poisons and venoms are comprised of different classes of molecules displaying wide-ranging pharmacological activities. This review aims to provide an in-depth view of toxin-based compounds from terrestrial and marine organisms used as diagnostic tools, experimental molecules to validate postulated therapeutic targets, drug libraries, prototypes for the design of drugs, cosmeceuticals, and therapeutic agents. However, making these molecules applicable requires extensive preclinical trials, with some applications also demanding clinical trials, in order to validate their molecular target, mechanism of action, effective dose, potential adverse effects, as well as other fundamental parameters. Here we go through the pitfalls for a toxin-based potential therapeutic drug to become eligible for clinical trials and marketing. The manuscript also presents an overview of the current picture for several molecules from different animal venoms and poisons (such as those from amphibians, cone snails, hymenopterans, scorpions, sea anemones, snakes, spiders, tetraodontiformes, bats, and shrews) that have been used in clinical trials. Advances and perspectives on the therapeutic potential of molecules from other underexploited animals, such as caterpillars and ticks, are also reported. The challenges faced during the lengthy and costly preclinical and clinical studies and how to overcome these hindrances are also discussed for that drug candidates going to the bedside. It covers most of the drugs developed using toxins, the molecules that have failed and those that are currently in clinical trials. The article presents a detailed overview of toxins that have been used as therapeutic agents, including their discovery, formulation, dosage, indications, main adverse effects, and pregnancy and breastfeeding prescription warnings. Toxins in diagnosis, as well as cosmeceuticals and atypical therapies (bee venom and leech therapies) are also reported. The level of cumulative and detailed information provided in this review may help pharmacists, physicians, biotechnologists, pharmacologists, and scientists interested in toxinology, drug discovery, and development of toxin-based products. (AU)

FAPESP's process: 17/14035-1 - Improving of human fragment antibodies (scFvs) specific for animals' venoms
Grantee:Felipe Augusto Cerni
Support type: Scholarships in Brazil - Post-Doctorate
FAPESP's process: 18/14158-9 - Improving of human fragment antibodies (scFvs) specific for animals' venoms
Grantee:Felipe Augusto Cerni
Support type: Scholarships abroad - Research Internship - Post-doctor
FAPESP's process: 18/21233-7 - Mass spectrometry analysis of a new phosphodiesterase from Crotalus durissus collilineatus venom
Grantee:Isadora Sousa de Oliveira
Support type: Scholarships abroad - Research Internship - Doctorate
FAPESP's process: 19/10173-6 - Production, modification and characterization of animal toxins with potential biotechnological application
Grantee:Eliane Candiani Arantes Braga
Support type: Regular Research Grants
FAPESP's process: 16/04761-4 - Functional and structural characterization and immune response evaluation of a recombinant serine protease from Crotalus durissus collilineatus modified by PEGylation
Grantee:Ernesto Lopes Pinheiro Junior
Support type: Scholarships in Brazil - Doctorate (Direct)
FAPESP's process: 17/04724-4 - Improving of human fragment antibodies (scFVs) specific for animals' venoms
Grantee:Eliane Candiani Arantes Braga
Support type: Regular Research Grants
FAPESP's process: 13/26200-6 - Venomics Plataform of Pachycondyla villosa Proteome, Transcriptome, Cloning and Expression of toxins with biotechnological potential
Grantee:Camila Takeno Cologna
Support type: Scholarships in Brazil - Post-Doctorate
FAPESP's process: 13/26619-7 - Comparative proteomic study of Crotalus durissus terrificus white and yellow venoms, with emphasis on hyaluronidase and L-amino acid oxidase enzymes
Grantee:Karla de Castro Figueiredo Bordon
Support type: Scholarships abroad - Research
FAPESP's process: 17/03580-9 - Biochemical, structural and functional evaluation of a phosphodiesterase from Crotalus durissus collilineatus venom
Grantee:Isadora Sousa de Oliveira
Support type: Scholarships in Brazil - Doctorate
FAPESP's process: 17/00586-6 - Characterization of a phospholipase A2 inhibitor from the Crotalus durissus terrificus venom gland: a possible adjuvant in the antivenom therapy
Grantee:Gisele Adriano Wiezel
Support type: Scholarships in Brazil - Doctorate